New Data Confirm Safety Of GT Medical’s GammaTile Therapy For Brain Tumors
Executive Summary
GT Medical is touting results from a validation study showing its GammaTile therapy controls the regrowth of brain tumors with a low rate of adverse events.
You may also be interested in...
GT Medical Technologies Raises $16M To Expand Brain Tumor Therapy
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Start-Up Spotlight: GT Medical Technologies' GammaTile Brings Brachytherapy Directly To Brain Tumors
Arizona-based GT Medical Technologies is ramping up commercialization of its GammaTile surgically targeted radiation therapy for patients with recurrent intracranial neoplasms. GammaTile already received 510(k) clearance, but continues to develop clinical evidence showing that GammaTile improves control of brain cancer following excision surgery and prolongs patient-survival.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.